

# Lisette M SchÃ¼tte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8187087/publications.pdf>

Version: 2024-02-01

10  
papers

49  
citations

1937685  
4  
h-index

1720034  
7  
g-index

10  
all docs

10  
docs citations

10  
times ranked

104  
citing authors

#	ARTICLE	IF	CITATIONS
1	The association between desmopressin exposure, FVIII response and side effects. Haemophilia, 2021, 27, e506-e509.	2.1	0
2	Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. Clinical Pharmacokinetics, 2021, 60, 1-16.	3.5	3
3	The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority?. Haemophilia, 2020, 26, 916-922.	2.1	3
4	Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target. Haemophilia, 2019, 25, 960-968.	2.1	4
5	Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. BMJ Open, 2019, 9, e022719.	1.9	7
6	von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. Blood Advances, 2019, 3, 4147-4154.	5.2	12
7	Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. Therapeutic Drug Monitoring, 2019, 41, 192-212.	2.0	10
8	VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD. Blood, 2019, 134, 1116-1116.	1.4	0
9	Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. Thrombosis and Haemostasis, 2018, 47, 621-629.	3.4	8
10	Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies. Blood, 2015, 126, 3510-3510.	1.4	2